Literature DB >> 31044385

Reversible alopecia areata: a little known side effect of leflunomide.

Greg Koller1, Ina Cusnir1, Jill Hall2, Carrie Ye3.   

Abstract

Leflunomide is a disease-modifying anti-rheumatic drug (DMARD) used in the management of rheumatoid arthritis (RA) and psoriatic arthritis. Commonly reported adverse effects include diarrhea, nausea, hepatotoxicity, hypertension, and transient global hair loss; however, additional side effects may be associated with the medication not reported in the monograph. We describe a rare case of reversible alopecia areata (AA) associated with the use of leflunomide and provide a literature review of three published similar cases. We use the Naranjo adverse drug reaction score to show the AA in our case is a "probable" side effect of leflunomide. Currently, AA is not listed as an adverse effect in the leflunomide product monograph. However, it would appear that based on our case and the three other reported cases, the likelihood of AA being an adverse effect of leflunomide is at least possible to probable.

Entities:  

Keywords:  Adverse effect; Alopecia areata (AA); Leflunomide; Side effect

Mesh:

Substances:

Year:  2019        PMID: 31044385     DOI: 10.1007/s10067-019-04577-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  5 in total

1.  Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide.

Authors:  Jacques-Eric Gottenberg; Pierre-Yves Venancie; Xavier Mariette
Journal:  J Rheumatol       Date:  2002-08       Impact factor: 4.666

2.  Recalcitrant alopecia areata responsive to leflunomide and anthralin-Potentially undiscovered JAK/STAT inhibitors?

Authors:  Kabir Sardana; Aastha Gupta; Ram K Gautam
Journal:  Pediatr Dermatol       Date:  2018-10-15       Impact factor: 1.588

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

4.  Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey.

Authors:  Morgan Schultz; Stephanie O Keeling; Steven J Katz; Walter P Maksymowych; Dean T Eurich; Jill J Hall
Journal:  Clin Rheumatol       Date:  2017-05-27       Impact factor: 2.980

Review 5.  [Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review].

Authors:  María Ignacia Molina Molina; Carmen María Pinochet Paiva; José Ignacio Quezada Morales
Journal:  Medwave       Date:  2015-12-30
  5 in total
  6 in total

1.  Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata.

Authors:  Kabir Sardana; Aastha Gupta; Pulin Kumar Gupta
Journal:  Clin Rheumatol       Date:  2019-07-23       Impact factor: 2.980

2.  Response: Leflunomide: potential treatment and cause of alopecia areata.

Authors:  Greg Koller; Jill Hall; Carrie Ye
Journal:  Clin Rheumatol       Date:  2019-07-23       Impact factor: 2.980

3.  Effects of Pereskia aculeate Miller Petroleum Ether Extract on Complete Freund's Adjuvant-Induced Rheumatoid Arthritis in Rats and its Potential Molecular Mechanisms.

Authors:  Yifei Chen; Kaifei Liu; Yingyuan Qin; Suyi Chen; Guokai Guan; Yao Huang; Yu Chen; Zhixian Mo
Journal:  Front Pharmacol       Date:  2022-05-09       Impact factor: 5.988

Review 4.  A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses.

Authors:  Yucheng Zheng; Shiliang Li; Kun Song; Jiajie Ye; Wenkang Li; Yifan Zhong; Ziyan Feng; Simeng Liang; Zeng Cai; Ke Xu
Journal:  Viruses       Date:  2022-04-28       Impact factor: 5.818

Review 5.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

6.  N-Butanol Extract of Gastrodia elata Suppresses Inflammatory Responses in Lipopolysaccharide-Stimulated Macrophages and Complete Freund's Adjuvant- (CFA-) Induced Arthritis Rats via Inhibition of MAPK Signaling Pathway.

Authors:  Peng He; Yiwen Hu; Changzhao Huang; Xi Wang; Heng Zhang; Xianping Zhang; Houjie Dai; Ruiying Wang; Yan Gao
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-21       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.